FIELD: medicine. SUBSTANCE: one should detect lymphocytes CD4+Leu8+, CD8+11b+, CD21+, CD2+, monocytes (M) and spontaneous (SS) and phytohemagglutinin-induced (RBT) DNA syntheses. By using these values it is possible to find the following ratios: . Moreover, predicted patient's life duration is considered to be that range of its values that corresponds for all mentioned ratios upon calibrated curves preplotted as dependence of life duration in patients of control group against each of mentioned ratios of their initial blood values. EFFECT: higher efficiency of prediction. 9 dwg, 3 ex, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTION OF CLINICAL OUTCOMES OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS | 2009 |
|
RU2426991C2 |
METHOD FOR PREDICTING THE OUTCOME OF SQUAMOUS CELL CARCINOMA OF THE TONGUE AND OROPHARYNX | 2019 |
|
RU2708786C1 |
METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
METHOD FOR LIFESPAN EVALUATION IN PATIENTS WITH LOCALLY ADVANCED AND DISSEMINATED RENAL CELL CARCINOMA | 2009 |
|
RU2405150C1 |
METHOD OF PREDICTING THE DEVELOPMENT OF METASTASES IN PATIENTS WITH UNRESECTABLE TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2802141C1 |
METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
METHOD FOR PREDICTING THE DURATION OF A RELAPSE-FREE PERIOD IN PATIENTS WITH RESECTABLE THRICE-NEGATIVE BREAST CANCER | 2021 |
|
RU2780922C1 |
METHOD FOR TREATING PRIMARY OVARIAN CANCER | 2004 |
|
RU2248824C1 |
METHOD FOR PREDICTION OF ESOPHAGEAL CANCER PROGRESSION | 2016 |
|
RU2640954C1 |
METHOD FOR PREDICTION OF EFFECTIVENESS OF CONSERVATIVE TREATMENT OF OROPHARYNGEAL SQUAMOUS CELL CARCINOMA | 2023 |
|
RU2817324C1 |
Authors
Dates
2004-01-27—Published
2003-04-22—Filed